Astrazeneca Merck Face Nice Setback In Bid For Broader Lynparza Use | Latest News RSS feed

Astrazeneca Merck Face Nice Setback In Bid For Broader Lynparza Use - Latest News


AstraZeneca, Merck face NICE setback in bid for broader Lynparza use

AstraZeneca and Merck & Co.’s Lynparza recently put up ovarian cancer data that blew away pharma watchers at a European Society for Medical Oncology meeting, and it’s been broadening its reach with ... read more

The biggest winners--and losers--in the 2015 race for new drug approvals

What was remarkable was the presence of Pfizer ($PFE), Sanofi ($SNY), AstraZeneca ($AZN) and Amgen ($AMGN ... keep rising higher and higher. Merck ($MRK) didn't have much to boast about in the NDA ... read more

AstraZeneca chief strikes defiant tone after drug disappointment

The setback comes at an awkward time for Mr Soriot, who put his ability to revitalise the company’s R&D at the heart of his case to investors for repelling a bid ... Merck that he said would maximise ... read more

Looking for another news?


England's Cancer Drugs Fund: Fixing a broken system

But in England, the question of access to these medicines has for more than 15 years been answered by NICE - a body ... Anglo-Swedish firm AstraZeneca said it would not even bother putting its newly ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us